Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | YTHDC1 | Q96MU7 | 9/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PDE8A | O60658 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12537196 | 0.84 | YTHDC1 (0.44) | ALDH1A1CYP1A2CYP3A4HSD17B10CASP1 | |
| SCHEMBL944764 | 0.80 | PIK3CA (0.60) | ALDH1A1CYP1A2HSD17B10CASP1PIK3CA | |
| SCHEMBL948660 | 0.79 | P2RX7 (0.41) | ALDH1A1CYP1A2HSD17B10YTHDC1CYP2C19 | |
| SCHEMBL946795 | 0.79 | KDR (0.41) | YTHDC1PIK3CAPDE8ACNR2 | |
| SCHEMBL17078391 | 0.76 | CDK5 (0.52) | PIK3CA | |
| SCHEMBL944935 | 0.74 | P2RX7 (0.46) | YTHDC1NR3C1PDE8AP2RY1CNR2 | |
| SCHEMBL947819 | 0.72 | XDH (0.47) | ALDH1A1YTHDC1CYP2C19 | |
| SCHEMBL948659 | 0.72 | CDK5 (0.38) | YTHDC1PIK3CA | |
| SCHEMBL12910231 | 0.69 | PIK3CA (0.54) | PIK3CA | |
| SCHEMBL12537337 | 0.69 | ADORA2B (0.40) | ALDH1A1HSD17B10YTHDC1PDE8AP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009403-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | S*BIO PTE LTD. (SG) | 2011-01-13 | — | — | US | disclosed |
| US-20110009403-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | S*BIO PTE LTD. (SG) | 2011-01-13 | — | — | US | disclosed |
| US-20110009403-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | S*BIO PTE LTD. (SG) | 2011-01-13 | — | — | US | disclosed |
| EP-2209785-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | S*BIO Pte Ltd (SG) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009045174-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | S*BIO PTE LTD (SG) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045174-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | S*BIO PTE LTD (SG) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009403-A1 | 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K | PIK3CA, TPMT, MTOR | ALDH1A1 3121/4885CYP1A2 2013/4885CYP3A4 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.